Clinical Trial Update: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of TJ107 combined with PD-1 in patients with solid tumors, including triple-negative breast cancer and head and nec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• PD-1 inhibitor
• TJ107

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING